EARLY AND NON INVASIVE METHOD FOR ASSESSING A SUBJECT'S RISK OF HAVING PANCREATIC DUCTAL ADENOCARCINOMA AND METHODS OF TREATEMENT OF SUCH DISEASE

摘要

The present invention relates to antagonist of βig-h3 protein, for use in the treatment of PDAC. The inventors found that βig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing βig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response. Thus, neutralizing βig-h3 which acts as a novel immunological check-point target in cancer therefore allows to restore beneficial anti-tumor immunity in cancer.